New Delhi, July 15, 2022 (GLOBE NEWSWIRE) — The global ADC market is growing at an impressive CAGR. The growing advancement in linker technologies, coupled with extensive research & development in the medical field, is driving the growth of the global ADC market…
A recent study by the strategic consulting and market research firm BlueWeave Consulting revealed that the Global ADC market was worth USD 4,053.7 million in 2021. The market is further anticipated to reach USD 14,484.2 million in 2027 with a significant CAGR of 25.2% during the forecast period, i.e., 2022-2027. The increasing incidence of cancer cases across the globe is propelling the growth of the global ADC (antibody-drug conjugate) market. For instance, according to the American Cancer Society, the estimated number of new cancer cases and deaths recorded for 2021 were around 1.9 million and 608,570, respectively, across the United States. In the coming years, ADC drug development will be facilitated by the increasing number of governmental healthcare programs and grants awarded to certain research organizations. Such factors, coupled with an increasing number of FDA approvals positively impact the growth of the global ADC Market.
Rising Number of Trials Pertaining to ADC Drugs Creating Lucrative Opportunities for Market Growth
The American Cancer Society estimates 36 ongoing trials with more than 20 ADCs combined with immuno-oncology (IO) therapies. With an estimated 100+ clinical trials…
